دورية أكاديمية
أعرض في EDS

Pharmacokinetics of Carboplatin in Combination with Low-Dose Cyclophosphamide in Female Dogs with Mammary Carcinoma.

التفاصيل البيبلوغرافية
العنوان: Pharmacokinetics of Carboplatin in Combination with Low-Dose Cyclophosphamide in Female Dogs with Mammary Carcinoma.
المؤلفون: Machado MC; Department of Veterinary Anatomy, Pathology and Clinics, School of Veterinary Medicine and Zootechny, UFBA, Salvador 40170-110, BA, Brazil., Yamamoto PA; Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA.; School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto 14040-903, SP, Brazil., Pippa LF; Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA., de Moraes NV; Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA., Neves FMF; Pharmacokinetics Laboratory, School of Pharmacy, Federal University of Bahia, Salvador 40170-115, BA, Brazil., Portela RD; Laboratory of Immunology and Molecular Biology, Institute of Health Sciences, Federal University of Bahia, Salvador 40231-300, BA, Brazil., Barrouin-Melo SM; Department of Veterinary Anatomy, Pathology and Clinics, School of Veterinary Medicine and Zootechny, UFBA, Salvador 40170-110, BA, Brazil., Hielm-Björkman A; Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, P.O. Box 57, 00014 Helsinki, Finland., Godoy ALPC; Pharmacokinetics Laboratory, School of Pharmacy, Federal University of Bahia, Salvador 40170-115, BA, Brazil., Estrela-Lima A; Department of Veterinary Anatomy, Pathology and Clinics, School of Veterinary Medicine and Zootechny, UFBA, Salvador 40170-110, BA, Brazil.; Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, P.O. Box 57, 00014 Helsinki, Finland.; Research Center on Mammary Oncology NPqOM/HOSPMEV, Federal University of Bahia, Salvador 40170-110, BA, Brazil.
المصدر: Animals : an open access journal from MDPI [Animals (Basel)] 2022 Nov 10; Vol. 12 (22). Date of Electronic Publication: 2022 Nov 10.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Molecular Diversity Preservation International Country of Publication: Switzerland NLM ID: 101635614 Publication Model: Electronic Cited Medium: Print ISSN: 2076-2615 (Print) Linking ISSN: 20762615 NLM ISO Abbreviation: Animals (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : Molecular Diversity Preservation International, 2011-
مستخلص: This prospective study aimed to evaluate the effect of metronomic cyclophosphamide on carboplatin’s tolerability, efficacy, and pharmacokinetics in dogs with mammary carcinoma. Sixteen female dogs with mammary carcinoma were divided into groups: 300 mg/m2 intravenous (i.v.) carboplatin therapy (G1 = 8) or 300 mg/m2 i.v. carboplatin which was associated with 12.5 mg/m2 oral cyclophosphamide in a metronomic regimen (G2 = 8). The investigated animals underwent a clinical evaluation, a mastectomy, a carboplatin chemotherapy, and serial blood sampling for the pharmacokinetic analysis. The adverse events and survival rates were monitored. A non-compartmental analysis was applied to calculate the pharmacokinetic parameters of carboplatin in the 2nd and 4th chemotherapy cycles. Carboplatin PK showed high interindividual variability with a 10-fold variation in the area under the plasma concentration−time curve (AUC) in G1. The systemic plasma exposure to carboplatin was equivalent in both of the treatments considering the AUC and maximum plasma concentration (Cmax) values. Although the red blood cells (p < 0.0001), platelets (p = 0.0005), total leukocytes (p = 0.0002), and segmented neutrophils (p = 0.0007) were reduced in G2, the survival rate increased (p = 0.0044) when it was compared to G1. In conclusion, adding low daily doses of cyclophosphamide to a carboplatin therapy showed promising outcomes in female dogs with mammary tumors.
References: J Am Vet Med Assoc. 2018 Jun 1;252(11):1377-1383. (PMID: 29772973)
Cancer Chemother Pharmacol. 1987;20(4):271-6. (PMID: 3319277)
Vet Clin North Am Small Anim Pract. 2014 Sep;44(5):941-63. (PMID: 25174909)
Reprod Sci. 2009 Nov;16(11):1097-102. (PMID: 19657143)
Geburtshilfe Frauenheilkd. 2016 May;76(5):525-534. (PMID: 27239061)
Cancer Treat Rev. 2020 Sep;89:102066. (PMID: 32769038)
Mol Pharmacol. 2009 Feb;75(2):324-30. (PMID: 18996970)
Nat Rev Clin Oncol. 2010 Aug;7(8):455-65. (PMID: 20531380)
Vet Comp Oncol. 2015 Jun;13(2):124-32. (PMID: 23714139)
Cancer Res. 2002 Dec 1;62(23):6938-43. (PMID: 12460910)
J Clin Pharmacol. 1988 Mar;28(3):208-15. (PMID: 3283185)
Crit Rev Oncol Hematol. 2012 Apr;82(1):40-50. (PMID: 21641231)
Top Companion Anim Med. 2009 Aug;24(3):137-43. (PMID: 19732732)
Clin Pharmacol Ther. 2010 Aug;88(2):150-2. (PMID: 20592719)
J Small Anim Pract. 2014 Jul;55(7):369-74. (PMID: 24803081)
Mol Pharmacol. 2006 Oct;70(4):1390-4. (PMID: 16847145)
Clin Cancer Res. 2008 Jan 1;14(1):270-80. (PMID: 18172279)
Cancer Chemother Pharmacol. 2016 Jun;77(6):1103-24. (PMID: 26886018)
J Vet Intern Med. 1993 Jul-Aug;7(4):235-40. (PMID: 8246213)
Biomed Chromatogr. 2010 Aug;24(8):908-13. (PMID: 20041399)
Clin Cancer Res. 2004 Jul 15;10(14):4661-9. (PMID: 15269138)
Drugs. 2000;59 Suppl 4:19-27. (PMID: 10864227)
Vet Comp Oncol. 2018 Mar;16(1):2-11. (PMID: 28317239)
Vet Comp Oncol. 2022 Mar;20(1):179-188. (PMID: 34390295)
Vet Comp Oncol. 2018 Dec;16(4):497-504. (PMID: 29806156)
Vet Comp Oncol. 2016 Dec;14(4):417-446. (PMID: 28530307)
In Vivo. 2018 Nov-Dec;32(6):1659-1666. (PMID: 30348731)
In Vivo. 2012 May-Jun;26(3):375-9. (PMID: 22523289)
BMC Vet Res. 2019 Nov 8;15(1):401. (PMID: 31703601)
Cancer Lett. 2015 Mar 28;358(2):100-106. (PMID: 25541061)
Drug Discov Today. 2013 Feb;18(3-4):193-201. (PMID: 22868084)
Vet Clin North Am Small Anim Pract. 2014 Sep;44(5):817-29. (PMID: 25174901)
Vet Comp Oncol. 2020 Dec;18(4):804-810. (PMID: 32452107)
Cancer Res. 2000 Apr 1;60(7):1878-86. (PMID: 10766175)
PLoS One. 2018 Oct 4;13(10):e0204830. (PMID: 30286124)
معلومات مُعتمدة: 023/2014 Fundação de Amparo à Pesquisa do Estado da Bahia; 310248/2021-3 National Council for Scientific and Technological Development; 312022/2021-2 National Council for Scientific and Technological Development; 313350/2019-1 National Council for Scientific and Technological Development; 001 Coordenação de Aperfeicoamento de Pessoal de Nível Superior
فهرسة مساهمة: Keywords: breast cancer; carboplatin; dog; metronomic chemotherapy; pharmacokinetic parameters; survival rate
تواريخ الأحداث: Date Created: 20221126 Latest Revision: 20230308
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9686876
DOI: 10.3390/ani12223109
PMID: 36428336
قاعدة البيانات: MEDLINE
الوصف
تدمد:2076-2615
DOI:10.3390/ani12223109